Wang Li

Dr. Wang Li

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2021 in Liver International
Verified
Journal Article
Closed access
PDF file
WLWang Li
Wang Li
YQYi‐Ling Qiu
Yi‐Ling Qiu
HXHong‐Mei Xu
Hong‐Mei Xu
JZJing Zhu
Jing Zhu
SLShuang‐Jie Li
Shuang‐Jie Li
JWJianshe Wang
Jianshe Wang

23 May 2022 in Liver International
Verified
Journal Article
Closed access
ZLZhong‐Die Li
Zhong‐Die Li
KAKuerbanjiang Abuduxikuer
Kuerbanjiang Abuduxikuer
WLWang Li
Wang Li
CHChen‐Zhi Hao
Chen‐Zhi Hao
JZJing Zhang
Jing Zhang
JWJianshe Wang
Jianshe Wang

1 December 2023 in Human Gene Therapy
Verified
Journal Article
Closed access
YZYanan Zhang
Yanan Zhang
DTDingyue Tang
Dingyue Tang
WLWang Li
Wang Li
JYJing Yang
Jing Yang
XWXia Wu
Xia Wu
JWJianshe Wang
Jianshe Wang
Zinc finger FYVE-type containing 19 (ZFYVE19) deficiency, caused by biallelic ZFYVE19 complete loss-of-function variants, is a recently identified chronic hepatobiliary disorder characterized by obvious portal-tract fibrosis, increased numbers of bile ducts with malformations, and abnormal levels of serum markers of hepatobiliary injury. As liver-targeted adeno-associated virus (AAV) gene therapy has been used successfully in hepatobiliary diseases, liver-targeted gene therapy has been explored in a mouse model of this disorder. Three ZFYVE19 AAV vectors (AAV-hZFYVE19, AAV-hZFYVE19-m, and AAV-hZFYVE19-co) were constructed and injected into Zfyve19-/- mice, which were treated with alpha-naphthyl isothiocyanate (ANIT), a hepatobiliary toxin. Hematoxylin/eosin (H&E), immunohistochemical (IHC) staining, immunofluorescence (IF) staining, Sirius red staining, RT-qPCR, and western blotting (WB) of liver tissue, along with serum hepatobiliary injury markers analyses, were performed to evaluate the effects of gene therapy. AAV-hZFYVE19 decreased serum hepatobiliary injury markers, portal-tract inflammation, ductal hyperplasia, and portal-tract fibrosis in Zfyve19-/- model mice most substantially at a relatively low dose (1 × 1011 vg/kg), whereas AAV-hZFYVE19 at a higher dose gradually lost the above-mentioned benefits and even caused deterioration at the highest dose of 5 × 1012 vg/kg. These observations verified the pathogenicity of ZFYVE19 deficiency and suggested that the ZFYVE19 gene needs to function well at an optimal level of expression; both too low or too high ZFYVE19 expression may be harmful.

7 January 2026 in Pediatric Investigation
Verified
Journal Article
Open access
WLWang Li
Wang Li
YYYue Yu
Yue Yu
JFJiayan Feng
Jiayan Feng
YZYanan Zhang
Yanan Zhang
RWRenxue Wang
Renxue Wang
JWJianshe Wang
Jianshe Wang
Importance: The production of tetrahydroxylated bile acids (THBAs) is associated with better prognosis in some cholestatic patients as well as in multidrug resistance protein 2 knockout ( Mdr2 −/− ) mice. However, it remains unclear whether this protective effect is specific to Mdr2 −/− mice. Objective: To evaluate the effects of THBA (3α,6α,7α,12α‐Tetrahydroxy‐10β,13β‐pentanoic acid) in Zfyve19 −/− mice, a newly developed mouse model characterized by cholestatic liver injury. Methods: THBA was administered to Zfyve19 −/− mice challenged with alpha‐naphthyl isothiocyanate (ANIT). Serum biochemistry, liver histology and immunostaining, and quantitative PCR for hepatic expression of pro‐fibrotic, pro‐inflammatory, and bile acid metabolism‐related genes were performed and compared against ANIT‐treated wild‐type and Zfyve19 −/− mice fed normal chow. Results: THBA administration reduced serum alanine aminotransferase ( P  < 0.001) and total bile acid levels ( P  < 0.001), decreased necrosis ( P = 0.046), portal inflammation ( P  < 0.001), bile duct hyperplasia ( P = 0.007), and portal fibrosis ( P = 0.002) in liver histology, along with a significant reduction in hepatic expression of pro‐fibrotic genes ( Acta2 , Col1a1 , Tgfb1 , Tgfb2 , and Timp1 ), as well as the pro‐inflammatory cytokines Tnf and macrophage chemokines ( Ccl2 , Cxcl1 , Cxcl9 , Cxcl10 , and Nos2 ). Additionally, the mRNA expression of Nr1h4 was profoundly upregulated, while key enzymes involved in bile acid synthesis were downregulated. Interpretation: THBA effectively alleviated cholestatic liver injury and fibrosis, and may represent a potential agent for the medical management of such diseases.

19 March 2026 in Hepatology
Verified
Journal Article
Closed access
YCYe Cheng
Ye Cheng
ZLZhong-Die Li
Zhong-Die Li
ZGZhi-Hong Guan
Zhi-Hong Guan
WLWang Li
Wang Li
YQYi-Ling Qiu
Yi-Ling Qiu
JWJianshe Wang
Jianshe Wang
Background & Aims: Since DNA sequencing alone faces challenges in variant interpretation during genetic diagnosis, RNA sequencing has recently gained attention in resolving these diagnostic gaps. This study aimed to evaluate the advantages of liver tissue RNA sequencing in the diagnosis of genetic liver diseases. Approach & Result: Liver tissue RNA sequencing was performed on 147 patients with prior DNA sequencing. We evaluated the role of RNA sequencing by analyzing aberrant gene expression, splicing, allele-specific expression, transcript-level similarity and mosaic variants. Liver RNA-seq supported the molecular diagnoses in 56 patients diagnosed by DNA sequencing alone. Among 91 previously undiagnosed patients, incorporating RNA sequencing established a diagnosis in 17 (18.68%) patients. Among the 33 patients with indicative clinical phenotypes or prioritized variants, diagnosis was established in 15 (45.45%) patients under the help of RNA sequencing. This improvement was primarily (16/17) driven by the detection of aberrant splicing and allele-specific expression, instead of aberrant expression. RNA sequencing revealed ±50bp of cryptic splicing sites as hotspot regions, characterized allele-specific expression at both the gene and variant levels and revealed shared transcriptomic features in low GGT cholestasis. Conclusions: While DNA sequencing demonstrates superior sensitivity in detecting clinically relevant variants, liver RNA sequencing significantly enhances genetic diagnosis mainly by revealing aberrant splicing and allele-specific expression. These findings suggest that RNA sequencing is an essential complement to DNA sequencing. Export

27 July 2023 in Human Mutation
Verified
Journal Article
Open access
PDF file
WLWang Li
Wang Li
YQYi-Ling Qiu
Yi-Ling Qiu
KAKuerbanjiang Abuduxikuer
Kuerbanjiang Abuduxikuer
NWNeng-Li Wang
Neng-Li Wang
ZLZhong-Die Li
Zhong-Die Li
JWJianshe Wang
Jianshe Wang
Biallelic MYO5B variants have been associated with familial intrahepatic cholestasis (FIC) with low serum gamma-glutamyltransferase (GGT). Intronic or synonymous variants outside of canonical splice sites (hereinafter referred to as noncanonical variants) with uncertain significance were identified in MYO5B posing a challenge in clinical interpretation. This study is aimed at assessing the effects of these variants on premessenger RNA (pre-mRNA) splicing to improve recognition of pathogenic spliceogenic variants in MYO5B and better characterize the MYO5B genetic variation spectrum. Disease-associated MYO5B noncanonical variants were collected from the literature or newly identified low GGT cholestasis patients. In silico splicing predictions were performed to prioritize potential pathogenic variants. Minigene splicing assays were performed to determine their splicing patterns, with confirmation by blood RNA analysis in one case. Eleven (five novel) noncanonical variants with uncertain significance were identified. Minigene splicing assays revealed that three variants (c.2090+3AT, c.2414+5GT, and c.613-11GA) caused complete aberrations, five variants (c.2349AG/p.(=), c.4221GA/p.(=), c.1322+5GA, c.1669-35AC, and c.3045+3AT) caused predominant aberrations, and three variants (c.4852+11AG, c.455+8TC, and c.2415-6CG) had no effect on pre-mRNA splicing. Patient-derived RNA analysis showed consistent results. Based on our results, eight variants were reclassified as likely pathogenic and three as likely benign. Combining the clinical features and the above analysis, the diagnosis of MYO5B-associated FIC could be made in three new patients. In conclusion, we characterized the splicing patterns of MYO5B noncanonical variants and suggest that RNA analysis should be routinely included in clinical diagnostics to provide essential evidence for the interpretation of variants.